[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 9060
1. King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AG, Pechnick RN, Lowenstein PR, Castro MG: Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits. Mol Ther; 2008 Apr;16(4):682-690
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits.
  • : Glioblastoma multiforme (GBM) is an invasive and aggressive primary brain tumor which is associated with a dismal prognosis.
  • We hypothesized that the growth of a large intracranial tumor mass would cause behavioral abnormalities that can be reversed by the combined gene therapy.
  • We assessed the behavior and neuropathology of tumor-bearing animals treated with the combined gene therapy, 3 days after treatment, in long-term survivors, and in a recurrent model of glioma.
  • These findings can serve to underpin further developments of this therapeutic modality, leading toward implementation of a Phase I clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178463.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Puri RK, Russell SJ, Galanis E: Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity. Mol Ther; 2008 Sep;16(9):1556-1564
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity.
  • : The majority of glioblastoma multiforme (GBM) tumors (80%) overexpress interleukin-13 receptor α2 (IL-13Rα2), but there is no expression of IL-13Rα2 in normal brain.
  • Vaccine strains of measles virus have significant antitumor activity against gliomas.
  • MV-GFP-H<sub>AA</sub>-IL-13 was generated from the Edmonston-NSe vaccine strain, by displaying human IL-13 at the C-terminus of the H protein, and introducing CD46 and signaling lymphocyte activation molecule (SLAM)-ablating mutations in H.
  • The IL-13 retargeted virus showed significant cytopathic effect (CPE) against IL-13Rα2 overexpressing glioma lines, and lack of CPE/viral replication in normal human astrocytes and normal human fibroblasts not expressing IL-13Rα2.
  • Strains of measles virus retargeted against the glioma-specific IL-13Rα2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28189011.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Antonio Chiocca E, Saeki Y: Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses. Mol Ther; 2008 Sep;16(9):1546-1555
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discovered that the yield of viral progeny increased significantly when cultured glioma cells were treated with HDAC inhibitors before viral infection.
  • Valproic acid (VPA), a commonly used antiepileptic agent with HDAC inhibitory activity, proved most effective when used to treat glioma cells before viral infection, but not concomitantly with viral infection.
  • Moreover, VPA pretreatment improved the propagation and therapeutic efficacy of oncolytic HSV in a human glioma xenograft model in vivo.
  • These findings indicate that HDAC inhibitors can improve the efficacy of tumor virotherapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28189010.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ma KH, Cheung KL: Nasal glioma. Hong Kong Med J; 2006 Dec;12(6):477-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal glioma.
  • Nasal gliomas are uncommon congenital lesions arising from abnormal embryonic development.
  • Histologically, they are made up of astrocytes and neuroglial cells, embedded in fibrous and vascular connective tissue.
  • Proper management of a nasal glioma requires a multidisciplinary approach including an otorhinolaryngologist, radiologist, and neurosurgeon.
  • The mainstay of treatment is conservative surgical excision because nasal gliomas are slow-growing, rarely recurrent, and have no malignant potential.
  • We report one case of nasal glioma in a Chinese infant.
  • A review of the clinical features of and diagnostic approach to nasal gliomas is also presented.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17148805.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. López-González A, Galeano I, Gutiérrez A, Giner R, Alvarez-Garijo JA, Cabanes J: [Association between cerebral infarction and malignant glioma]. Rev Neurol; 2005 Jan 1-15;40(1):34-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between cerebral infarction and malignant glioma].
  • [Transliterated title] Asociación de infarto cerebral y glioma maligno.
  • Only three cases have been reported in which cerebral infarction is thought to have been caused by the arterial compromise triggered by incipient high grade gliomas that are not yet visible in radiological tests.
  • Magnetic resonance imaging of the brain revealed the presence of a highly malignant tumour in the previously infarcted territory.
  • Therefore, in the presence of a cerebral infarct in patients with no risk factors for suffering a brain vascular pathology, it is advisable to carry out a radiological follow-up so as to be able to diagnose a possible lesion due to a tumour.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696424.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Assencio-Ferreira VJ, Mussi ML, Guirado VM, Veiga JC: [Transient lesion in the splenium of the corpus callosum in epileptic child with cerebral low grade glioma]. Arq Neuropsiquiatr; 2005 Mar;63(1):171-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transient lesion in the splenium of the corpus callosum in epileptic child with cerebral low grade glioma].
  • [Transliterated title] Lesão transitória no esplênio do corpo caloso em criança epiléptica com glioma cerebral de baixo grau.
  • We report on a seven years-old boy with complex partial seizures and the presence of low grade glioma in left fronto-parietal region.
  • Thus, the observed transient focal lesion in the splenium of the corpus callosum of this child, probably, has correlation with to prolonged focal partial seizures and not to the presence of glioma low grade.
  • [MeSH-major] Brain Neoplasms / diagnosis. Corpus Callosum / pathology. Epilepsy, Complex Partial / diagnosis. Glioma / diagnosis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830087.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine
  •  go-up   go-down


7. González-Aguilar A, Gutiérrez-Castrellón P, Briceño E, Rembao-Bojórquez D, Alonso-Vilatela ME, Rasmussen A: [Increased risk of neoplasia among relatives of glioma patients]. Rev Neurol; 2008 Oct 1-15;47(7):343-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increased risk of neoplasia among relatives of glioma patients].
  • [Transliterated title] Incremento en el riesgo de neoplasia entre familiares de pacientes con glioma.
  • INTRODUCTION: Some previous studies have suggested familial aggregation of gliomas, although the results have not always been replicated.
  • SUBJECTS AND METHODS: In the present study of a Mexican population, we compared 100 cases of glioma with 124 healthy unrelated controls, as well as their 1st, 2nd and 3rd degree relatives (n = 3,575 and 4,520 respectively).
  • RESULTS: The relatives of the cases had a significantly higher risk of developing brain tumors than the relatives of controls (OR = 5.3; p < 0.05; 95% CI = 1.1-25.7), and their risk of developing any cancer was also increased (OR = 2; p < 0.05; 95% CI = 1.16-3.51), this risk was twofold for men when compared to females (OR = 2; p < 0.05; 95% CI = 1.15-3.37).
  • CONCLUSION: The present study supports familial aggregation of brain tumors and warrants further research into their genetic etiology.
  • [MeSH-major] Brain Neoplasms. Genetic Predisposition to Disease. Glioma

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841544.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ: Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas. Neurosurgery; 2006 Jun 01;58(6):1009-1107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173306.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Parsa AT, Waldron J, Parney I, Sison C, Stokoe D, Tihan T, Pieper R: 850 Glioma Patients Segregate into Two Distinct Immunosuppresssive Phenotypes Based on PTEN Status: Implications for Immunotherapy. Neurosurgery; 2005 Aug 01;57(2):412
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 850 Glioma Patients Segregate into Two Distinct Immunosuppresssive Phenotypes Based on PTEN Status: Implications for Immunotherapy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184806.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Tseng JH, Tseng MY: 919 Survival Analysis for Children with Glioma in England and Wales. Neurosurgery; 2005 Aug 01;57(2):436-437
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 919 Survival Analysis for Children with Glioma in England and Wales.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184838.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Fountas KN, Kapsalaki EZ: Volumetric Assessment of Glioma Removal by Intraoperative High-field Magnetic Resonance Imaging. Neurosurgery; 2005 May 01;56(5):E1166
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric Assessment of Glioma Removal by Intraoperative High-field Magnetic Resonance Imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184800.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Synowitz M, Markovic D, Chirasani S, Vinnakota K, Holmbeck K, Lehnardt S, van Rooijen N, Heppner F, Kaminska B, Kettenmann H, Glass R: Glioma Induce and Exploit Microglial Membrane Type 1 Metalloprotease Expression for Tumor Expansion: 974. Neurosurgery; 2009 Aug 01;65(2):425
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma Induce and Exploit Microglial Membrane Type 1 Metalloprotease Expression for Tumor Expansion: 974.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173380.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kim SK, Black PM, Kim SU, Cargioli T, Sun Y, Al-Hashem R, Machluf M, Carroll R: 847 PEX-producing Human Neural Stem Cells Inhibit Tumor Growth in a Mouse Glioma Model. Neurosurgery; 2005 Aug 01;57(2):411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 847 PEX-producing Human Neural Stem Cells Inhibit Tumor Growth in a Mouse Glioma Model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184774.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Nimsky C, Ganslandt O, Fahlbusch R: Volumetric Assessment of Glioma Removal by Intraoperative High-field Magnetic Resonance Imaging. Neurosurgery; 2005 May 01;56(5):E1166
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric Assessment of Glioma Removal by Intraoperative High-field Magnetic Resonance Imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184705.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yu JS, Liu G, Ng H, Wagenberg M, Luptrawan A, Mindlin E, Wheeler CJ, Black KL: A Phase I Trial of Intracranial Dendritic Cell Immunotherapy for Patients with Malignant Glioma 894. Neurosurgery; 2006 Aug 01;59(2):485-486
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I Trial of Intracranial Dendritic Cell Immunotherapy for Patients with Malignant Glioma 894.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180735.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sughrue ME, Parsa AT: Newly Discovered NK-cell/Dendritic Cell Duality: Potential Implications for Glioma Immunotherapy. Neurosurgery; 2006 Aug 01;59(2):N9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly Discovered NK-cell/Dendritic Cell Duality: Potential Implications for Glioma Immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180641.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bredel M, Renfrow J, Yadav A, Alvarez A, Lin D, Scholtens D, He X, Chandler J, Scheck A, Harsh G: Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2028
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2028 Background: Glioblastoma multiforme is a complex disease that involves the deregulation of overlapping signaling pathways.
  • METHODS: Multidimensional analysis involving gene and transcript data for the endogenous NF-κB modulator IκBα/NFKBIA and clinical patient profiles of 482 glioblastomas/high-grade gliomas from multiple institutions in the United States and The Cancer Genome Atlas Pilot Project.
  • IκBα promoter and coding sequence and promoter methylation analyses in a resistance model of 15 glioblastomas cell lines with in vitro and/or in vivo resistance to O6-alkylating agents.
  • Functional analyses uncover a bona fide tumor suppressor role for IκBα in glioblastoma cells, where it functions to constrain tumorigenic and migratory potential, and induce spontaneous cellular senescence, and apoptosis in response to treatment.
  • Glioblastomas with initially high IκBα expression significantly repress IκBα upon tumor recurrence, suggesting an acquired mechanism to evade its tumor-suppressive and/or chemo-sensitizing effects during tumor progression.
  • CONCLUSIONS: IκBα is a molecular determinant of biological tumor behavior and patient survival in glioblastoma multiforme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964596.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. J Clin Oncol; 2009 May 20;27(15_suppl):2060
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults.
  • Five patients achieved a partial response (83%); in one patient the disease was stable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yu JS, Black KL, Liu G, Wheeler CJ, Wagenberg M, Das A, Mindlin E, Chu RM, Luptrawan A, Badruddoja MA: 843 Results of a Phase II Trial of Tumor Lysate-pulsed Dendritic Cell Vaccination for Malignant Glioma. Neurosurgery; 2005 Aug 01;57(2):409-410
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 843 Results of a Phase II Trial of Tumor Lysate-pulsed Dendritic Cell Vaccination for Malignant Glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184776.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gilbert MR, Wang M, Aldape K, Lassman A, Sorensen AG, Mikkelson T, Groves M, Werner-Wasik M, Regine W, Mehta M: RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2011
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2011 Background: Angiogenesis is a hallmark of GBM, making the tumor vasculature an attractive therapeutic target.
  • In gliomas, vascular endothelial growth factor (VEGF) promotes both angiogenesis and invasion of tumor cells.
  • Irinotecan may enhance efficacy by synergistic tumor endothelial cell death or improved tumor delivery of the chemotherapy via "normalized" tumor vasculature.
  • METHODS: Eligibility included age ≥ 18, centrally confirmed GBM or gliosarcoma, progressive or recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021661
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gupta S, Sheikh H, Schneider C, Zhang X, Padmanabhan A, Ali A: HER-2/neu expression in glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):e13035
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13035 Background: Glioblastoma multiforme (GBM) is a disease in which very few cytotoxic chemotherapy agents have been shown to have activity.
  • Trials with bevacizumab, a VEGF inhibitor that disrupts tumor angiogenesis, have demonstrated activity against this otherwise chemotherapy resistant disease.
  • Over-expression of HER-2/neu by human tumor cells is closely associated with increased angiogenesis and expression of VEGF.
  • In a recent study, breast cancer patients treated with lapatinib and capcitabine had decreased brain metastases indicating that lapatinib may cross the blood brain barrier and thus have potential in the treatment of malignant gliomas.
  • METHODS: Archival histopathologic sections from 41 patients (age 26-89 years) with a diagnosis of GBM from 2004-2008 were reviewed.
  • The diagnosis was confirmed and optimal sections were selected.
  • Three cases demonstrated weak, incomplete membrane staining of rare tumor cells (score 1+) and were interpreted as negative.
  • This suggests that HER-2/neu over-expression is not a significant oncogenic pathway in GBM, and therefore may not be a potential therapeutic target in this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962861.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Horbinski C, Mintz A, Engh J, Lieberman F, Hamilton RL, Park DM: Post-therapeutic changes in the molecular profile of glioblastomas. J Clin Oncol; 2009 May 20;27(15_suppl):2026
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2026 Background: Glioblastoma multiforme is the most common and malignant primary brain tumor in adults.
  • Despite aggressive surgery, radiation, and chemotherapy, average survival time after diagnosis is about 1 year.
  • Analyses were performed on tumor tissue obtained at initial diagnosis and at first recurrence.
  • 24% of previously non-EGFR-amplified tumors acquired low-grade amplification (less than 10 copies/chromosome 7 CEP signal) after treatment, and 16% of EGFR-amplified tumors lost amplification after treatment.
  • CONCLUSIONS: Our results suggest that the molecular profile of these tumors is dynamic and that certain key alterations, including acquisition of low-level EGFR amplification in previously EGFR-negative tumors, occurs in a subset of cases.
  • Such alterations may contribute to therapy resistance as the glioma evolves in a changing microenvironment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Fiveash JB, Chowdhary SA, Peereboom D Jr, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2010
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A prior study of racemic gossypol demonstrated objective responses in patients with malignant glioma.
  • Radiographic assessment of tumor response was made at q 8-week intervals.
  • Seven patients (16%) had stable disease as the best response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Chen M, Osman I, Orlow SJ: Effect of celastrol on temozolomide cytotoxicity in melanoma cells and inhibition of NF-kB signaling. J Clin Oncol; 2009 May 20;27(15_suppl):9076
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have identified celastrol as a natural product that significantly enhances TMZ-induced cytotoxicity by testing a library of drugs and natural products for cytotoxic activity against glioma and melanoma cell lines and have examined its mechanism of action in melanoma cells.
  • METHODS: A preliminary screening of a library of 2000 drugs and natural products was performed and a short list of drugs was identified as able to enhance TMZ-induced cell killing in TMZ-resistant cancer cell lines.
  • The effects of these compounds were further confirmed in five melanoma cell lines.
  • A cell proliferation assay was used to compare growth inhibitory effects of single agent TMZ versus combination treatments.
  • Synergy in inhibiting cell proliferation was assessed using combination-index methods.
  • The effect of treatments on the cell cycle was examined by flow cytometry.
  • RESULTS: Combining celastrol and TMZ synergistically inhibited cell proliferation, enhanced cell cycle arrest, and increased apoptosis in a series of melanoma cell lines, compared to treatment with TMZ alone.
  • Inhibition of NF-kB with siRNA mimicked the ability of celastrol to sensitize melanoma cells to TMZ-induced cell killing, suggesting inhibition of NF-kB was indeed involved in TMZ/celastrol-induced cytotoxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962182.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Aghi MK, Rabkin S, Martuza RL: 840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair. Neurosurgery; 2005 Aug 01;57(2):408-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184805.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Carter B, Aghi MK, Curry WT, Barker FG: 851 Supratentorial Low-grade Glioma: Diagnostic Trends and Temporal and Geographic Variation in Practice Patterns-A Population-based Study. Neurosurgery; 2005 Aug 01;57(2):412
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 851 Supratentorial Low-grade Glioma: Diagnostic Trends and Temporal and Geographic Variation in Practice Patterns-A Population-based Study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184771.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Tseng MY, Tseng JH, Merchant E: Effects of Socioeconomic and Geographic Variations on Survival for Adult Glioma in England and Wales: A Population-based Study 860. Neurosurgery; 2006 Aug 01;59(2):474
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Socioeconomic and Geographic Variations on Survival for Adult Glioma in England and Wales: A Population-based Study 860.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180704.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Tong Z, Wanibuchi M, Uede T, Tanabe S, Hashi K: Significant Improvement of Visual Functions after Removal of an Intracranial Giant Optic Nerve Glioma Revealing Exophytic Growth. Neurosurgery; 2006 Apr 01;58(4):E792
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant Improvement of Visual Functions after Removal of an Intracranial Giant Optic Nerve Glioma Revealing Exophytic Growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180530.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yu JS, Yuan X, Liu G, Zeng Z, Morris-Irvin D, Black KL: 848 Interleukin-23-expressing Bone Marrow-derived Neural Stem-like Cells Exhibit Antitumor Activity against Intracranial Glioma. Neurosurgery; 2005 Aug 01;57(2):411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 848 Interleukin-23-expressing Bone Marrow-derived Neural Stem-like Cells Exhibit Antitumor Activity against Intracranial Glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184785.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Field M, Bushnev S, Alvarez AA, Avgeropoulos N, Sugaya K: Markers Distinguishing Cancer Stem Cells from Normal Human Neuronal Stem Cell Populations in Malignant Glioma Patients: 978. Neurosurgery; 2009 Aug 01;65(2):426
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers Distinguishing Cancer Stem Cells from Normal Human Neuronal Stem Cell Populations in Malignant Glioma Patients: 978.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28175631.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kim SK, Choi SA, Hwang SK, Cho BK, Phi JH, Wang KC: Targeted Delivery of TRAIL-producing Human Adipose Tissue-Derived Mesenchymal Stem Cells into Experimental Brainstem Glioma: 951. Neurosurgery; 2009 Aug 01;65(2):417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted Delivery of TRAIL-producing Human Adipose Tissue-Derived Mesenchymal Stem Cells into Experimental Brainstem Glioma: 951.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173334.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Pollak MN, Blouin M, Zakikhani M, Zhao Y, Algire C: Dependence of malignant proliferation associated with loss of PTEN on glucose concentration in the hyperglycemic range: Relevance to population studies linking hyperglycemia to unfavorable cancer prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):11113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11113 Background: Loss of function of the tumor suppressor PTEN enhances malignant proliferation, but effects on cellular energy metabolism are less well characterized.
  • METHODS: We used a tetracycline-inducible PTEN expression vector in the PTEN-null U251 glioma cell line to characterize effects of PTEN on cellular energy metabolism.
  • The data also suggest that PTEN status is relevant to selection of tumors likely to respond to experimental therapies that exploit glucose dependency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Akella NS, Nabors LB, Rosenfeld SS, Chamberlain MC, Mrugala MM, Jacoby DB, O'Neill AM: A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects. J Clin Oncol; 2009 May 20;27(15_suppl):2041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro data demonstrate binding to vascular endothelial cells, and blockage of endothelial cell invasion.
  • Based on this work and previous clinical trials demonstrating tumor-specific uptake of <sup>131</sup>I-TM601 in malignant glioma after IV delivery, a phase I trial was initiated with intravenous unlabeled TM-601.
  • All patients received a test dose of 10 mCi <sup>131</sup>I-TM601 to demonstrate tumor-specific uptake prior to TM601 treatment at doses of 0.04 mg/kg IV weekly for 3 weeks in a 4 week cycle.
  • Treatment continued until tumor progression.
  • Three other serious adverse events considered to be unrelated to therapy included disease progression on therapy, a hip fracture and renal calculi in a patient with a history of renal calculi.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964654.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Sarkaria JN, Galanis E, Wu W, Giannini C, Jaeckle KA, Doyle L, Uhm J, Brown P, Dietz AB, Buckner J: NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J Clin Oncol; 2009 May 20;27(15_suppl):2019
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2019 Background: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival.
  • We previously demonstrated significant synergy of the mTOR inhibitor sirolimus with RT in glioma xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S: NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2001 Background: EMD 121974 (cilengitide) is a selective integrin receptor inhibitor that is well tolerated and has demonstrated biological activity in patients with malignant glioma.
  • To date, 89 out of 112 patients were alive 12 months from their initial diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964566.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Boku N, Yamazaki K, Yamamoto N, Takahashi T, Fukutomi A, Miyazaki M, Satoh T, Okamoto I, Nakagawa K, Fukuoka M: Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):e14574
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan.
  • : e14574 Background: Nimotuzumab, a humanized IgG1 monoclonal antibody targeting EGFR, has been used in head & neck cancer or malignant glioma outside Japan, and MTD including severe skin rash were not observed up to 800mg/body.
  • METHODS: Pts with advanced solid tumors having no available standard therapy were enrolled.
  • Blood, skin samples before treatment and after 4th infusion and pre-treatment tumor were collected for PD analysis.
  • A correlation between anti-tumor activity and EGFR amplification was speculated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hu J, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F: Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2009
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2009 Background: Gimatecan is a highly lipophilic oral camptothecin analogue with impressive preclinical activity in glioma models.
  • Eligibility criteria included ≤1 prior treatment for recurrent disease, age ≥18, ECOG performance status 0 or 1, and normal organ function.
  • Only one patient had a partial radiographic response by the modified Macdonald criteria and stable disease was the best response in 13 patients.
  • All other patients had progressive disease after two cycles of therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964558.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Oettle H, Hilbig A, Seufferlein T, Schmid RM, Luger T, von Wichert G, Schmaus S, Heinrichs H, Schlingensiepen K: Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4619
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It also plays a crucial role in tumor progression by regulating metastasis, angiogenesis, and proliferation.
  • Trabedersen, a TGF-beta 2-specific inhibitor has already shown a clear survival benefit in a randomized active-controlled phase II study in high-grade glioma patients, compared to standard chemotherapy.
  • Of the 5 melanoma patients one from the 1st schedule showed stable disease and lived for 13.8 months; 3 patients from the 2nd schedule are still alive.
  • Current mOS for pancreatic carcinoma patients in cohort 1 (N=5) of the 2nd schedule is 13.2 months; 2 of these patients are alive, one with stable disease 14.8 months after begin of trabedersen treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Geoerger B, Hargrave D, Thomas F, Andreiuolo F, Varlet P, Frappaz D, Doz F, Riccardi R, Jaspan T, Vassal G, European Innovative Therapies for Children with Cancer (ITCC) Consortium: Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):10019
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas.
  • METHODS: Group 1 included patients with brain tumors refractory to or relapsing after conventional therapy; receiving erlotinib alone.
  • Group 2 included newly diagnosed patients with brain stem gliomas, who received RT (54Gy) and erlotinib.
  • In Group 1, 8 patients (27.6%) had stable disease, 2 with 45% tumor regression.
  • Biomarker analyses on archived tumor or biopsy tissue prior to study entry for newly diagnosed brain stem glioma found 18/37 tumors tested were EGFR IHC+; 16/37 and 23/36 were pAKT+ and pMAPK+, respectively.
  • High EGFR expression was more common in supratentorial gliomas; PTEN loss was most common in brain stem glioma (15/19) and was not observed in ependymomas.
  • CONCLUSIONS: Erlotinib 125 mg/m<sup>2</sup>/day has an acceptable tolerability profile in pediatric patients with brain tumors, and can be safely combined with RT.
  • Further studies are required to define the efficacy of this treatment approach and to establish the impact of biomarkers on outcomes in pediatric glial tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962504.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Mora J, Cruz O, Parareda A, Guillen A, Puy R, Massaguer S, de Torres C, Garcia G, Costa JM: Treatment of childhood glial tumors with cisplatin and irinotecan. J Clin Oncol; 2009 May 20;27(15_suppl):10062
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood glial tumors with cisplatin and irinotecan.
  • : 10062 Background: Childhood glial tumors are heterogeneous neoplasias for which non-surgical management is controversial.
  • RESULTS: From January 2004 to December 2007, 30 children aged 6 months to 17 years were treated, 21 at diagnosis, 7 at progression and 2 at relapse.
  • Fourteen tumors were WHO grades I-II gliomas (LGG), 10 grade III (6 gliomas, 2 anaplastic ependymomas and 2 AT/RT), and 6 had no biopsy (3 brainstem (BST) and 3 optic-pathway tumors (OPT)).
  • Prior to the I/C regimen, gross total resection was performed in 7 and biopsy in 14 tumors; 9 patients received chemotherapy and 5 radiotherapy.
  • All but 6 patients, 2 because of C allergy and 4 BST because of progression, completed the protocol, with no grade 3-4 side effects.
  • With a median follow-up of 25 months, 14 (47%) patients had a complete/partial response (7 out of 10 HG), 10 (40%) had stable disease (8 out of 14 LG), and 6 (20%) progressed (all BST).
  • Five patients died of disease, all BST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962497.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Del Maestro RF, Siu V, Seyed Sadr M, Alshami J, Sabau C, Seyed Sadr E, Samani A, Assadian S, Greaves K, Pouliot J: The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients. J Clin Oncol; 2009 May 20;27(15_suppl):e13027
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The temozolomide O6-methylguanine-DNA methyltransferase (MGMT) study: A phase II trial to evaluate the effect of low-dose preoperative neoadjuvant temozolomide on brain tumour MGMT activity in glioma patients.
  • : e13027 Background: Epigenetic methylation of the O6-methylguanine-DNA methyltransferase (MGMT) DNA repair gene promoter in tumor tissue from glioblastoma multiforme patients is associated with improved survival after treatment with radiotherapy plus concomitant and adjuvant temozolomide (TMZ).
  • We hypothesized that MGMT promoter methylation mosaicism exists in glial tumors and would affect response to TMZ.
  • Twenty-three patients with brain tumors detected by MRI scan and suspected to be gliomas were evaluated.
  • The primary goal of the study was to evaluate the effect of TMZ 75 mg/m<sup>2</sup> daily prior to surgery on the brain tumor MGMT expression.
  • Secondary endpoints included safety, tolerability, and MGMT promoter methylation mosaicism in glial tumors.
  • Samples were obtained from multiple regions of each tumor intra-operatively and were analyzed by methylation specific PCR.
  • RESULTS: Our results on MGMT promoter methylation demonstrate that three groups of patients can be identified: Type I: all sites assessed in the tumor demonstrate no methylation of the MGMT promoter; Type II: all sites demonstrate high levels of MGMT promoter methylation; and Type III: a mixed promoter methylation pattern is observed.
  • 2) glial tumors can have very heterogeneous areas of MGMT promoter methylation; and 3) three patterns of MGMT promoter methylation can be discerned.
  • This experimental paradigm may be a useful experimental platform for the assessment of the effect of new drugs at the tumor level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Siegelin M: KAAD-cyclopamine sensitize malignant glioma cells to TRAIL-mediated apoptosis. J Clin Oncol; 2009 May 20;27(15_suppl):2025
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KAAD-cyclopamine sensitize malignant glioma cells to TRAIL-mediated apoptosis.
  • : 2025 Background: Malignant gliomas are the most aggressive human brain tumors without any curative treatment.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic because TRAIL induces almost selectively apoptosis in cancer cells.
  • In the present study we found that the Hedgehog inhibitor, KAAD-cyclopamine, potently sensitized primary glioma cells to TRAIL-mediated apoptosis.
  • METHODS: Established cell lines and isolated primary tumor glioblastoma cells were treated with achievable plasma concentrations of TRAIL, KAAD-cyclopamine, or the combination of both.
  • For transfection experiments primary glioma cells were electroporated with plasmids encoding the cDNA of c-FLIP and bcl-2.
  • RESULTS: We established a stable culture model for isolated primary human glioma cells.
  • In contrast to cell lines, isolated primary tumor cells from all investigated glioma patients were highly TRAIL resistant.
  • Single treatment with KAAD-cyclopamine or TRAIL does not induce cytotoxicity in malignant glioma cells.
  • However, treatment with KAAD-cyclopamine in combination with TRAIL induces rapid apoptosis in TRAIL-resistant glioma cells.
  • CONCLUSION: The widespread TRAIL resistance in primary glioma cells described here questions the therapeutic clinical benefit of TRAIL as a monotherapeutic agent.
  • Overcoming TRAIL resistance by KAAD-cyclopamine cotreatment might, however, provide a powerful therapeutic option for glioma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964601.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Herndon J 2nd, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS: Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13016
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas.
  • : e13016 Background: Recurrent malignant gliomas have a poor prognosis, with a median survival of 6-15 months, with grade 4 glioblastomas more aggressive than grade 3 anaplastic astrocytomas or oligodendrogliomas.
  • Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) are critically important in glioma biology.
  • We report a phase I trial of vandetanib in combination with oral etoposide for recurrent malignant glioma.
  • METHODS: Patients with histologically documented recurrent grade 3 or grade 4 malignant glioma were eligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962830.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • We evaluated the addition of temozolomide (TMZ) to radiotherapy for newly diagnosed anaplastic gliomas in terms of tolerability, progression-free survival (PFS), and overall survival (OS).
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • CONCLUSIONS: The addition of temozolomide to radiation therapy for newly diagnosed anaplastic gliomas is well tolerated and seems active; efficacy needs confirmation in a randomized clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S: The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):2057
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab.
  • : 2057 Background: There is no standard of care for recurrent gliomas; however, bevacizumab is often used as a salvage chemotherapy regimen.
  • A diffuse, infiltrative pattern of recurrence, as evidenced by MR imaging, was seen manifesting as multifocal disease or presumed CSF dissemination with subependymal spread.
  • METHODS: We conducted a retrospective analysis of 40 recurrent glioma patients followed at Moffitt Cancer Center from September 2006 through December 2008 treated with bevacizumab alone or in combination with irinotecan.
  • CONCLUSIONS: There appears to be an increase in a diffuse, infiltrative pattern of recurrence among recurrent glioma patients treated with bevacizumab as a salvage regimen.
  • It is unclear why the disparity among this subset of patients occurs, however, we hypothesize that this may once again highlight the distinct tumor biology among young glioma patients.
  • The impact of this observation on clinical decision making on whether to utilize bevacizumab in young recurrent glioma patients warrants further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Sathornsumetee S, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Friedman HS, Reardon DA: Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2045
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.
  • : 2045 Background: Bevacizumab (B), a neutralizing VEGF monoclonal antibody, has anti-glioma activity as single agent and in combination with cytotoxic therapy.
  • Erlotinib (E), an EGFR tyrosine kinase inhibitor, may exhibit anti-tumor activity in some malignant glioma (MG) patients.
  • B plus E was associated with clinical benefit in several solid tumors.
  • RESULTS: Fifty-six patients with recurrent MG (n = 24 for glioblastoma multiforme [GBM] and n = 32 for anaplastic gliomas [AGs]) were assessable for outcome.
  • CONCLUSIONS: Among heavily pretreated recurrent MG patients, bevacizumab plus erlotinib is tolerated and associated with encouraging anti-tumor benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D: A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. Mol Ther; 2008 Mar;16(3):618-626
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma.
  • In an effort to improve the therapeutic index of IFN-β by providing local, sustained delivery of IFN-β to gliomas, the safety and biological activity of a human IFN-β (hIFN-β)-expressing adenovirus vector (Ad.hIFN-β) was evaluated in patients with malignant glioma by stereotactic injection, followed 4-8 days later by surgical removal of tumor with additional injections of Ad.hIFN-β into the tumor bed.
  • Ad.hIFN-β DNA was detected within the tumor, blood, and nasal swabs in a dose-dependent fashion and hIFN-β protein was detectable within the tumor.
  • At the highest doses tested, a reproducible increase in tumor cell apoptosis in post-treatment versus pre-treatment biopsies with associated tumor necrosis was observed.
  • Direct Ad.hIFN-β injection into the tumor and the surrounding normal brain areas after surgical removal was feasible and associated with apoptosis induction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178503.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Phuphanich S, Rudnick J, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Wheeler C, Singh M, Yu JS: A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2032
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma.
  • : 2032 Background: Previous immunotherapy trials for malignant glioma (Yu, J.,et al, Cancer Res.
  • 2001;61:842-7 and 2004;64;4973-9) have demonstrated efficacy in generating a tumor specific immune response.
  • Here we set out to determine feasibility and immunogenecity of dendritic vaccination with specific glioma-associated antigens.
  • METHODS: The goal of this study is to use tumor associated antigens (TAA) known to be expressed on gliomas and pulse dendritic cells with these antigens in an MHC compatible fashion using epitopes of HER-2, TRP-2, gp100, MAGE-1, IL13R alpha, and AIM-3.
  • Leukapheresis was used to isolate mononuclear cells which were differentiated into dendritic cells in culture, pulsed with tumor peptide, and then administered intradermally three times at 2-week intervals.
  • Our data on 19 patients and 54 courses of dendritic cell vaccines demonstrate zero grade 3 /4 toxicities that were attributable to the vaccination.
  • Thirteen patients continue to have stable disease (ranging from 15 to 115 weeks), six patients have demonstrated tumor progression.
  • Of 15 patients tested to date, six patients demonstrated an antigen-specific cytotoxic T-cell response to at least one antigen after vaccination.
  • Only 17% of CTL responders (1/6) demonstrated tumor progression compared to 56% (5/9) of nonresponders to date.
  • CONCLUSIONS: This phase I study demonstrated the feasibility, safety, and bioactivity of a TAA-pulsed dendritic cell vaccine for patients with glioblastoma progression free survival correlated with CTL response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964632.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Karrasch M, Gillespie GY, Braz E, Liechty PG, Nabors LB, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Markert JM: Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results. J Clin Oncol; 2009 May 20;27(15_suppl):2042
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.
  • Safety and efficacy of intracerebral inoculations of G207 to patients suffering from recurrent malignant gliomas have been demonstrated in previous clinical trials.
  • METHODS: In this phase I clinical trial, a total of 1 x 10<sup>9</sup> plaque forming units (pfu) G207 were administered by five stereotactic injections of 0.2 mL each into regions of recurrent malignant glioma defined by MRI, followed by focal radiation therapy 24 hours post injection.
  • The 2 patients with initial PR (1xGBM, 1xAA) were re-treated with G207/Irradiation at time point of tumor recurrence, showing PR one month after re-treatment again.
  • Within persistent areas of tumor, HSV staining was present by using a polyclonal antibody for HSV, indicating intratumoral G207 replication (proof of concept).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Lin Y, Jiang T, Li G: MGMT expression in low-grade gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT expression in low-grade gliomas.
  • : e13001 Background: To evaluate the expression of MGMT in low-grade gliomas, and explore the relationship between its expression and the histological type of the tumour and the corresponding MRI characteristics.
  • METHODS: We assessed 389 low-grade gliomas (182 astrocytomas, 145 oligoastrocytomas, 61 oligodendrocytomas) with immunohistochemistry staining.
  • We also recorded the preoperational MRI criteria such as tumor volume on T2 image, enhancing volume, tumor location, and relationship with ventricles.
  • MGMT expression level was significantly correlated with the enhancing volume of the tumor (r = -0.605, p = 0.002), but did not correlate with the total tumor volume (p = 0.504).
  • CONCLUSIONS: MGMT is more strongly expressed in tumors of solely astrocyte component, and its expression level is negatively correlated with the extent of blood-brain barrier disruption.
  • This suggest that MGMT may contribute to the tumor resistance to radiotherapy and chemotherapy in low-grade gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • : e13020 Background: Seizures are common in patients with glioma.
  • We compare seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: Retrospective analysis of consecutive patients with glioma.
  • RESULTS: 76 patients (34 female) with pathologically proven glioma and seizures were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ochsenbein AF, Schubert AD, Vassella E, Mariani L: Quantitative analysis of 0&lt;sup&gt;6&lt;/sup&gt;-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2069
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of 0<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
  • : 2069 Background: Loss of heterozygosity (LOH) on the chromosomes 1p and 19q is associated with sensitivity to alkylating agents like temozolomide (TMZ) in patients with low-grade gliomas; whether methylation of the MGMT-promoter, a predictive factor in glioblastoma patients, also correlates with tumor response to TMZ in low-grade gliomas is unclear.
  • METHODS: We performed a retrospective analysis of patients with histologically verified low-grade gliomas (WHO Grade II) who were treated with TMZ for tumor progression at our hospital between November 1999 and November 2007.
  • Objective tumor response was assessed by MRI at 6-month intervals.
  • LOH of microsatellite markers on chromosomes 1p and 19q was determined by polymerase chain reaction (PCR) amplification of the matched pairs of blood and tumor DNA.
  • Seven patients had prior surgical resection of the tumor.
  • CONCLUSIONS: Quantitative methylation-specific PCR of the MGMT promoter correlates with radiological response to chemotherapy with temozolomide in WHO grade II gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Soffietti R, Rudà R, Trevisan E, Picco E, Guarneri D, Caroli M, Fabrini M, Scotti V: Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. J Clin Oncol; 2009 May 20;27(15_suppl):2012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study.
  • : 2012 Background: Bevacizumab (BV) has shown a promising activity in recurrent malignant gliomas (MG) in combination with irinotecan.
  • The treatment consists of an induction phase with BV at 10 mg/kg intravenously on day 1 and 15 and fotemustine (FTM) (a nitrosourea with elevated lipophilic properties) at 75 mg/m<sup>2</sup> intravenously on day 1 and 8, followed after a 3-week interval by a maintenance phase with BV at 10 mg/kg i.v. and FTM 75 mg/m<sup>2</sup> i.v. every 3 weeks until tumor progression or unacceptable toxicity.
  • The co-primary endpoints are objective response rate (ORR), based on Mc Donald's criteria (CR + PR) and progression-free survival at 6 months (PFS6), with secondary endpoints of safety time to tumor progression (TTP) and overall survival.
  • RESULTS: From April 2008 to December 2008, 34 patients were enrolled and 31 (22 glioblastomas and 9 anaplastic gliomas) are evaluable for response.
  • Overall response rate (2 CR and 9 PR) was 35% (glioblastomas 33%, anaplastic gliomas 41.5%).
  • Fifteen patients are free of tumor progression (from 2 to 8 months).
  • CONCLUSIONS: Combination of bevacizumab and fotemustine in recurrent malignant gliomas is safe and promising.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964590.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Franceschi E, Tosoni A, Ermani M, Spagnolli F, La Torre L, Galzio RJ, Pozzati E, Talacchi A, Benevento F, Brandes AA: Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of MGMT methylation status on 1p/19q intact anaplastic gliomas.
  • : e13003 Background: Chromosomes 1p/19q codeletion has been recognized as a prognostic and predictive factor in patients (pts) with grade 3 gliomas.
  • Non-codeleted (intact) anaplastic oligodendroglioma showed a survival comparable to that usually observed in pts with anaplastic astrocytomas; MGMT methylation status, moreover, has been found to be a prognostic factor in glioblastoma and anaplastic gliomas (AG).
  • We evaluated only pts who met the following inclusion criteria: age ≥ 18 years; PS 0-2; histological diagnosis of AG with 1p/19q intact, as determined by FISH analysis; treatment with postoperative radiotherapy (RT) and chemotherapy (CT); MGMT status determined using methylation specific PCR.
  • No enhancement at time of diagnosis (p = 0.003), gross total resection (p = 0.03), age (p = 0.001), and MGMT methylation (p = 0.05) were significantly correlated with better PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Jones L, Friedman A, West M, Mabe S, Fraser J, Kraus W, Friedman H, Major N, Reardon D: Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma.
  • : e13002 Background: The neuropsychological impact of malignant glioma is well documented; the physiological and functional effects are not known.
  • We conducted a pilot study to quantitatively assess cardiorespiratiory fitness, skeletal muscle function, and body composition of patients with primary malignant glioma.
  • METHODS: Using a cross-sectional design, patients with clinically stable postsurgical (10 ± 7 days post surgery) high-grade glioma (HGG; n=25) and low-grade glioma (LGG) were studied.
  • RESULTS: CPET was a feasible and safe procedure for malignant glioma patients with no serious adverse events.
  • CONCLUSIONS: CPET is a safe and feasible tool to evaluate physical functioning in select patients with malignant glioma.
  • Postsurgical glioma patients have markedly reduced exercise capacity, isokinetic strength and CSA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962755.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Clin Oncol; 2009 May 20;27(15_suppl):e13030
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13030 Background: Alkylator-based chemotherapy is recognized to be leukemogenic, however, it is infrequently described as a delayed consequence of anti-glioma treatment.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • METHODS: Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients).
  • The diagnosis of tMDS was determined by bone marrow biopsy in seven patients.
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 months to 31 months (median 24 months).
  • Five patients have died, two as a consequence of recurrent brain tumor, one as a complication of transplantation, and due due to AML.
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Frentzas SN, Groves MD, Barriuso J, Harris D, Reardon D, Curtis MC, Suttle AB, Ma B, Lager JJ, de Bono JS: Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):2040
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study.
  • Combination of VEGFR, PDGFR, and ErbB1 inhibitors may provide synergistic antitumor activity in malignant glioma.
  • Phase II, which evaluated the efficacy of daily paz/lap (400 mg/1000mg) in relapsed grade 4 glioma without EIACs, was previously reported.
  • METHODS: Patients (pts) with grade 3 or 4 glioma, on EIACs, and with adequate organ function were eligible.
  • Responses and lengthy periods without disease progression were seen in some pts in phase I and II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Zitron IM, Norkina O, Al-Kadhimi Z, Barger GR, Lum LG, Mittal S: Targeting of glioblastoma with activated T cells armed with anti-CD3xanti-HER2/neu (HER2Bi) and anti-CD3xanti-EGFR (EGFRBi) bispecific antibodies. J Clin Oncol; 2009 May 20;27(15_suppl):3038
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3038 Background: Malignant gliomas are the most common primary brain tumors in adults.
  • HER2Bi- and/or EGFRBi-armed ATCs were examined for in vitro cytotoxicity (MTT and <sup>51</sup>Cr release assays) against long-term malignant glioma lines (U87MG, U118MG, and U251MG) as well as primary glioblastoma lines derived from surgical specimens.
  • Anti-CD133 coated magnetic microbeads were used to separate CD133-positive and CD133-negative cell populations.
  • HER2Bi-armed ATCs exhibited comparable cytotoxicity against U118 and U251, but did not kill HER2-negative glioma U87.
  • Cytotoxicity exhibited by either HER2Bi- or EGFRBi-armed ATCs against four primary glioblastoma cell lines was 50-80%.
  • We found that both CD133-negative and CD133-positive cell populations were susceptible to killing by armed ATCs.
  • When we armed ATCs simultaneously with HER2Bi and EGFRBi, killing by doubly armed ATCs was equal to or greater than that by EGFRBi-armed ATCs against the tested cell lines.
  • Long-term malignant glioma cell lines and primary lines derived from surgical specimens are equally susceptible.
  • Both CD133-negative and CD133-positive (the putative glioma stem cells) are killed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962074.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Chinot OL, Boudouresque F, Bequet C, Barrie M, Thiebaut A, Matta M, Autran D, Ouafik L: Correlation of serum urokinase plasminogen activator (uPA) to progression of recurrent malignant glioma during bevacizumab treatment: A marker of invasive phenotype and a candidate to monitor therapy. J Clin Oncol; 2009 May 20;27(15_suppl):2059
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of serum urokinase plasminogen activator (uPA) to progression of recurrent malignant glioma during bevacizumab treatment: A marker of invasive phenotype and a candidate to monitor therapy.
  • : 2059 Background: Identification of circulating markers that predict tumor response or reflect progression is of crucial importance when using antiangiogenic agents.
  • However, to date, no such parameters have been identified particularly for bevacizumab, for which, recently, increasing data have supported a role in patient with recurrent malignant glioma.
  • METHODS: Serial serum levels of VEGF, VEGFR2, FGF, SDFα, urokinase plasminogen activator (uPA), plasminogen activator inhibitor type I (PAI-1), and metalloprotesase type 9 (MMP9) were determined in a cohort of 32 patients treated with bevacizumab and irinotecan for recurrent malignant glioma.
  • CONCLUSIONS: Increase of uPA serum level appear to be correlated to disease progression for patients with recurrent malignant glioma treated with bevacizumab and may reflect the invasive phenotype of glioma progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964660.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M: Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13018
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of protracted dose-dense temozolomide (TMZ) in patients with progressive high-grade glioma.
  • : e13018 Background: The study was aimed to evaluate the efficacy of TMZ on a protracted dose-dense schedule after standard 5-day TMZ regimen in patients with progressive high-grade glioma.
  • METHODS: In this phase II prospective study, patients who had progression on standard 5-day TMZ for recurrence (group 1) or recurrence after concurrent radiotherapy+TMZ and ≥ 2 cycles of adjuvant TMZ (group 2) for high-grade glioma received TMZ 100 mg/m2× 21 q28 days until progression according to MacDonald's criteria.
  • The histopathology was glioblastoma in 18 and grade 3 glioma (anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma) in 7.
  • The best response during treatment was partial response in 2 (8%), stable disease in 9 (36%), and progression in 9 (36%) out of 20 patients assessed.
  • CONCLUSIONS: Protracted dose-dense TMZ after 5-day schedule for recurrent or progressive disease has modest efficacy with tolerable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Raizer JJ, Grimm S, Rice L, Muro K, Chandler J, Tellez C, Mellot AL, Newman S, Nicholas MK, Chamberlain M: A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2044
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas.
  • : 2044 Background: Increasingly target specific agents are used in the treatment of malignant gliomas (MG).
  • METHODS: All patients (pts) had to sign an IRB informed consent except six pts who were treated at a different site in a similar fashion.
  • Patients were assessed using Macdonald criteria and continued on trial until tumor progression or toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964646.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Khosla P, Monga V, Taaca A: Pilot study of topotecan and thalidomide in patients with recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13019
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of topotecan and thalidomide in patients with recurrent malignant gliomas.
  • : e13019 Background: Adults with glioblastoma multiforme (GBM) treated with radiation and chemotherapy have median survival of less than 12 months from diagnosis.
  • Topotecan is a topoisomerase-1 inhibitor with activity in brain tumors and very little nonhematologic toxicity.
  • METHODS: Single-center prospective phase II study of 10 patients (median age 50, range 38-70) with high-grade recurrent glioma treated at Rush University Medical Center between 2002 and 2006 following IRB approval.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962824.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol; 2009 May 20;27(15_suppl):2004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02).
  • METHODS: The North American Brain Tumor Consortium conducted a phase I/II study of the EGFR inhibitor erlotinib in combination with the mTOR inhibitor temsirolimus in recurrent MG.
  • Eligibility criteria were histologically proven GBM and anaplastic gliomas (AG), radiologic progression, >18 years old, KPS >60, adequate bone marrow and organ function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Rudnick JD, Phuphanich S, Chu R, Mazer M, Wang H, Serrano N, Francisco M, Black KL, Wheeler C, Yu J: A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2033
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
  • : 2033 Background: Our prior immunotherapy trials demonstrated efficacy in generating a tumor specific immune response in malignant glioma and the potential for high tumor-specific toxicity and sustained tumoricidal activity.
  • METHODS: We exploited this synergistic effect to maintain a cytotoxic environment around the tumor milieu.
  • Patients with high-grade glioma were eligible after maximal resection with biodegradable carmustine (BCNU) wafer placement.
  • Screening leukapheresis is used to isolate mononuclear cells which are differentiated into dendritic cells, pulsed with tumor lysate, and then 3 intradermal vaccines are administered at 2-week intervals.
  • Our preliminary data on 15 patients and 39 courses of Dendritic Cell vaccines demonstrate one grade 3 toxicity of fever/chest pain.
  • A stable disease interval of 13 to 90 weeks was observed for patients who received vaccine.
  • The 3 newly diagnosed GBM patients have stable disease (18 to 71 weeks).
  • CONCLUSIONS: This phase I study demonstrates the safety, feasibility of dendritic cell vaccination with biodegradable carmustine (BCNU) wafers with one grade 3 AE.
  • Immunological data is pending to determine potential synergy of dendritic cell vaccination with intracranial chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964627.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Rampling R, Sanson M, Taal W, Lai C, Stoffregen C, Munoz M, Gorlia T, Govaerts A, Lacombe D, Van den Bent M: Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054. J Clin Oncol; 2009 May 20;27(15_suppl):e13005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054.
  • METHODS: Patients (pts) with recurrent high-grade glioma or newly diagnosed disease not amenable to radiotherapy (RT) and WHO PS 0-1 were eligible.
  • Two pts showed a partial response, six pts stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962764.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Neyns B, Chaskis C, Dujardin M, Everaert H, Sadones J, Nupponen NN, Michotte A: Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2038
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma.
  • : 2038 Background: High-grade gliomas (HGG) are characterized by neo-angiogenesis.
  • Decrease in CBV<sub>LTN</sub> and CBF<sub>LTN</sub> was observed in 6/14 evaluable pts after 4 weeks of sunitinib, 5/19 evaluable pts had SD on T1±Gd after 8 weeks; one pt experienced a marked clinical improvement with a reduction in the tumor metabolism on PET.
  • Characterization of the VEGFR, PDGFR, and Kit gene copy numbers and protein expression in the tumors is ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA: Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol; 2009 May 20;27(15_suppl):2046
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.
  • : 2046 Background: Significant therapeutic benefit has been observed among recurrent malignant glioma (MG) patients treated with bevacizumab (BV), a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF) with or without chemotherapy.
  • CONCLUSIONS: Combination of bevacizumab and etoposide is well tolerated in recurrent MG patients and is associated with encouraging anti-tumor benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964642.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Bogdahn U, Schneider T, Oliushine V, Parfenov V, Mahapatra AK, Balasubramaniam A, Venkataramana N, Stockhammer G, Heinrichs H, Schlingensiepen K, and Trabedersen Glioma Study Group: Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. J Clin Oncol; 2009 May 20;27(15_suppl):2037
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints.
  • : 2037 Background: High-grade gliomas (HGG) strongly overexpress TGF-beta 2.
  • METHODS: The Phase IIb study AP 12009-G004 was an open-label, randomized, active-controlled dose-finding study.
  • RESULTS: AA and GBM patients in both trabedersen groups had long-lasting tumor responses (currently up to 4 years).
  • AA: (10 μM trabedersen vs. control): significantly better overall response rate was noted at 14 months (CR+PR; p=0.034*) and lower tumor progression rates at 6, 12 and 14 months; difference at 14 months was statistically significant (p=0.003*).
  • Tumor progression rate at 14 months and 2-year survival rate correlated with a median overall survival benefit of 17.4 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Friedman HS, Vredenburgh JJ, Desjardins A, Janney DE, Peters KB, Friedman AH, Gururangan S, Reardon DA: A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13024
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma.
  • : e13024 Background: Malignant glioma (MG), an incurable primary CNS tumor, are highly angiogenic due to overexpression of VEGF/VEGFR.
  • Evidence of therapeutic benefit to date includes 8 patients (73%) with stable disease including 3 who continue on therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962793.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA: Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13007
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.
  • : e13007 Background: Malignant glioma (MG), an incurable primary CNS tumor, is characterized by frequent aberrant activation of EGFR, VEGFR, and PDGFR.
  • Evidence of therapeutic benefit to date includes 1 partial response and 15 patients (58%) with stable disease for at least 4 weeks, including 4 patients for ≥4 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted R, O'Connor PC, Ryan RP, Recht L: A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema. J Clin Oncol; 2009 May 20;27(15_suppl):2080
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema.
  • : 2080 Background: Corticorelin acetate (CrA) is a synthetic peptide of corticotropin-releasing factor, undergoing clinical trials as a treatment for peritumoral edema in patients with cerebral tumors.
  • This study compared CrA therapy vs an increase in dexamethasone (dex) dose (+4 mg) for controlling symptoms in primary glioma patients with a subacute exacerbation.
  • The treatment groups had similar demographic and baseline disease characteristics.
  • Patients in the CrA arm reported more injection site erythema and flushing vs. the control arm.
  • CONCLUSIONS: CrA may be of value in managing patients with cerebral tumors who have subacute exacerbations of their symptoms, without needing to increase their dex dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Shen S, Nabors LB, Raizer JJ, Fiveash JB, Spies S, Costello R, O'Neill AM: Dosimetry study of a phase II multiple-dose intracavitary administration of &lt;sup&gt;131&lt;/sup&gt;I-TM601 in adult patients with recurrent high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetry study of a phase II multiple-dose intracavitary administration of <sup>131</sup>I-TM601 in adult patients with recurrent high-grade glioma.
  • : e13006 Background: Postoperative radiotherapy for glioma has been shown to improve survival with increased radiation doses.
  • Radiolabeled targeting molecules can deliver localized radiation to tumor and reduce normal brain radionecrosis.
  • TM601, or synthetic Chlorotoxin, is a peptide derived from scorpion venom that specifically binds to tumor cells.
  • Here we report dosimetry results of an imaging sub-study of a phase II trial, in which weekly doses of <sup>131</sup>I-TM601 were infused into surgically created tumor resection cavities for 3 or 6 weeks.
  • For each imaging study, 5 sequential SPECT images (1-168 hour) were registered with MRI to determine the <sup>131</sup>I-TM601 radiation dose to the 2-cm tumor cavity margin.
  • Median tumor cavity volume was 11.4 mL, and ranged 5.2 - 35.5 mL.
  • These results support the multi-dose fractionation scheme for <sup>131</sup>I-TM601 to minimize normal tissue toxicity, including radiation necrosis, and extend continuous irradiation to clinical or sub-clinical residual tumor cells after surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Fogh SE, Machtay M, Werner-Wasik M, Curran W, Bonanni R, Mallon G, Axelrod R, Andrews D, Dicker A: A phase I trial using patupilone (epothilone B) and concurrent radiotherapy for CNS malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e14504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligible patients had recurrent gliomas (10), primary (5), or metastatic (17) brain tumors.
  • Radiation treatment was determined by the patient's diagnosis.
  • CNS metastases received whole brain radiation with a median dose of 37.4 Gy in 1.8-2.5 Gy fractions and patients with recurrent gliomas received stereotactic radiotherapy with a median dose of 37.5 Gy in 2.0-3.5 Gy fractions.
  • Median overall survival was 12 months for recurrent gliomas, 15 months for primary brain tumors and 4 months for CNS metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963534.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Psimaras D, Sanson M, Delattre J: Bevacizumab and irinotecan for recurrent oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2054
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
  • : 2054 Background: Treatment with a regimen of bevacizumab/irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied.
  • METHODS: The bevacizumab/irinotecan regimen was retrospectively evaluated in a consecutive series of 25 patients with recurrent oligodendroglial tumors.
  • Among the 17 patients in whom the status of the main molecular alterations of gliomas could be evaluated (search for deletions of chromosomes 1p, 19q, 9p, 10q, and amplification of EGFR, MDM2, CDK4), no relation could be found between the response rate and the type of genetic change (including 1p-19q co-deletion).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964672.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Bello L, Acerbi F, Giussani C, Baratta P, Taccone P, Songa V: Intraoperative Language Localizationin Multilingual Patients with Gliomas. Neurosurgery; 2006 Jul 01;59(1):115-125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative Language Localizationin Multilingual Patients with Gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180605.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bristol RE, Rennert J, Coons S, Berens M: 861 Gene Expression Profiling of Pediatric Brainstem Gliomas. Neurosurgery; 2005 Aug 01;57(2):417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 861 Gene Expression Profiling of Pediatric Brainstem Gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184801.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Gabayan AJ, Green SB, Sanan A, Jenrette J, Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, Bastin KT, Watson G, Burri S, Stea B: GliaSite Brachytherapy for Treatment of Recurrent Malignant Gliomas. Neurosurgery; 2006 Apr 01;58(4):701-709
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GliaSite Brachytherapy for Treatment of Recurrent Malignant Gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180528.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • Radiographic evaluation reported: 2 partial responses, 14 stable disease for at least 4 cycles, and 11 disease progression after either the first or second cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP: Metabolic Remodeling Of Malignant Gliomas Forenhanced Sensitization During Radiotherapy: An In Vitro Study. Neurosurgery; 2006 Dec 01;59(6):1313-1324
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic Remodeling Of Malignant Gliomas Forenhanced Sensitization During Radiotherapy: An In Vitro Study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180803.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Bello L, Fava M, Gallucci M, Giussani C, Carrabba G, Acerbi F, Songa V, Conte V, Baratta P, Stocchetti N, Papagno C, Gaini S: Intraoperative Subcortical Language Tracts Mapping Guides Surgical Removal of Gliomas Involving Speech Areas 902. Neurosurgery; 2006 Aug 01;59(2):488
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative Subcortical Language Tracts Mapping Guides Surgical Removal of Gliomas Involving Speech Areas 902.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180731.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Roth J, Nass D, Ram Z: Cerebellar Tumor Extension as a Late Event of Long-standing, Supratentorial Low-grade Gliomas: Case Report. Neurosurgery; 2006 Jun 01;58(6):E1210
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar Tumor Extension as a Late Event of Long-standing, Supratentorial Low-grade Gliomas: Case Report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173119.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Yemisci M, Bozdag S, Çetin M, Söylemezoglu F, Çapan Y, Dalkara T, Vural I: Treatment Of Malignant Gliomas With Mitoxantrone-Loaded Poly (Lactide-Co-Glycolide) Microspheres. Neurosurgery; 2006 Dec 01;59(6):1296-1303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment Of Malignant Gliomas With Mitoxantrone-Loaded Poly (Lactide-Co-Glycolide) Microspheres.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180799.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Taking contraceptive pill may increase meningioma risk. Nurs Stand; 2010 Oct 20;25(7):17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Use of exogenous hormones, especially current use, appears to increase the risk of meningioma, but is not associated with glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019590.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Gribbin TE, Senzer N, Raizer JJ, Shen S, Nabors LB, Wiranowska M, Fiveash JB: A phase I evaluation of intravenous (IV) &lt;sup&gt;131&lt;/sup&gt;I-chlorotoxin delivery to solid peripheral and intracranial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I evaluation of intravenous (IV) <sup>131</sup>I-chlorotoxin delivery to solid peripheral and intracranial tumors.
  • : e14507 Background: Pre-clinical studies demonstrate TM601 binding to glioblastoma, melanoma, and other tumor types in vitro and in vivo (human xenograft tumors in mice).
  • Here we report imaging and safety data from a Phase I clinical trial in patients with recurrent metastatic somatic and/or cerebral solid tumors that received IV <sup>131</sup>I-TM601.
  • Subjects not showing tumor localization, received a second imaging test dose of 20 mC/0.4mg <sup>131</sup>I-TM601.
  • Subjects without localization at either dose were dropped from study; patients showing tumor localization without toxicity then received a 30 mCi/0.6mg <sup>131</sup>I-TM601 IV injection.
  • 31/44 (70%) showed tumor specific uptake on follow-up gamma camera or SPECT imaging.
  • Tumor-specific uptake was observed in patients with malignant glioma (7/8), metastatic melanoma (7/7), non-small cell lung cancer (3/4), colon cancer (6/7), pancreatic cancer (2/3), prostate cancer (2/2), breast cancer (1/4) and in one evaluable patient each with transitional cell carcinoma, pleomorphic xanthoastrocytoma and metastatic paraganglioma.
  • Notably, all patients with metastatic cerebral disease showed tumor-specific uptake of systemically injected <sup>131</sup>I-TM601.
  • No uptake was seen in CNS lymphoma (n=1), ovarian (n=2), small cell lung (n=2), or medulllary thyroid cancers (n=1).
  • CONCLUSIONS: Tumor-specific uptake of IV <sup>131</sup>I-TM601 in primary and metastatic (including brain) solid tumors suggests that further dose escalation is warranted.
  • Based on normal tissue dosimetry from this study, future clinical trials will evaluate safety and therapeutic efficacy in patients with recurrent glioma and metastatic melanoma at doses up to 100 mCi <sup>131</sup>I-TM601 (maximum single dose).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963538.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Nimsky C, Ganslandt O, Weigel D, Buchfelder M: Fiber Tract Navigation in Glioma Surgery 903. Neurosurgery; 2006 Aug 01;59(2):488-489
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fiber Tract Navigation in Glioma Surgery 903.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180709.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Chang EF, Keles EG, Potts M, Chang S, Lamborn KL, Barbaro NM, Berger MS: Seizure Characteristics and Postoperative Seizure Control in Patients with Low-grade Gliomas. Neurosurgery; 2005 Aug 01;57(2):430
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizure Characteristics and Postoperative Seizure Control in Patients with Low-grade Gliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184794.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Yang I, Parsa AT: An Enlightening Model of Glioma. Neurosurgery; 2005 Jan 01;56(1):N7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An Enlightening Model of Glioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184625.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Bian XW, Xiao HL, Yang SX, Wang JM: Preferential Expression of Chemokine Receptor CXCR4 by Highly Malignant Human Gliomas and Its Association with Poor Patient Survival. Neurosurgery; 2008 Oct 01;63(4):E820
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential Expression of Chemokine Receptor CXCR4 by Highly Malignant Human Gliomas and Its Association with Poor Patient Survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184868.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Broniscer A, Merchant TE, Hillenbrand C, Patay Z, Chin TK, Onar A, Kaste SC, Gilbertson RJ, Gajjar A: Phase I study of vandetanib (ZD6474) administered during and after irradiation (RT) in children with diffuse intrinsic pontine glioma (DIPG). J Clin Oncol; 2009 May 20;27(15_suppl):10020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vandetanib (ZD6474) administered during and after irradiation (RT) in children with diffuse intrinsic pontine glioma (DIPG).
  • Increased tumor perfusion during the first 6 weeks of therapy was observed in the first 12 patients analyzed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962620.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI: 893 High-resolution Mapping of Human Glioma Genomes. Neurosurgery; 2005 Aug 01;57(2):427-428
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 893 High-resolution Mapping of Human Glioma Genomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28184830.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Waldron J, Yang I, Murray JC, Cachola KE, Parsa AT: Akt/PKB Activation Facilitates Immune Escape in Glioma Patients 908. Neurosurgery; 2006 Aug 01;59(2):490
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt/PKB Activation Facilitates Immune Escape in Glioma Patients 908.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180752.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Pistollato F, Abbadi S, Rampazzo E, Viola G, Della Puppa A, Cavallini L, Panchision DM, Te Kronnie G, Basso G: Glioblastoma-derived cells exhibit differential responses to glycolysis inhibition under hypoxia. J Clin Oncol; 2009 May 20;27(15_suppl):e13031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13031 It has been suggested that oxygen tension is a crucial component of the brain tumor niche, as hypoxia positively correlates with tumor aggressiveness and over-activity of hypoxia inducible factor-1α (HIF-1α) reinforces tumor progression.
  • GBM account for 50% of all gliomas and arise after age 50 in most patients and it has been seen that younger patients tend to have a better prognosis than the elderly.
  • Furthermore, increase of multi-drug resistant cell fraction, described as side population, occurred following 2-DG treatment, but only under hypoxia.
  • Also, hypoxia inhibits the mitochondria-controlled apoptosis induced by 2-DG, by conferring cell resistance through progressive activation of pro-survival NF-kB and induction of tumor cell autophagy.
  • These results indicate differences in tumor cells behavior that may be predictive of cell response to therapy aiming to limit glucose uptake or glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol; 2009 May 20;27(15_suppl):2062
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • METHODS: Patients with recurrent histologically confirmed meningiomas and no more than two previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and eight (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 29%, 12-month PFS (PFS12) 0%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical/malignant tumors, PFS6 was 25%, PFS12 19%, OS6 81%, and OS12 68%.
  • Of 21 evaluable patients, there were no responses; eight patients (38%) had stable disease, and 13 (62%) had progressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Pośpiech L, Gawron W, Rak J, Bochnia M: [Nasal glioma--case report]. Otolaryngol Pol; 2005;59(5):767-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal glioma--case report].
  • [Transliterated title] Glioma nasi--doniesienie o przypadku.
  • Benign congenital lesions resulting from the deficient regression of neuroglial tissue in normal embryonic development are called gliomas.
  • They are included in the differential diagnosis of nasofrontal midline masses.
  • We present a case of the 9-year-old boy treated in the ENT Department of Wroclaw Medical University with the initial diagnosis of nasal polyposis or tumour which appeared to be glioma in the postoperative histological evaluation.
  • We present magnetic resonance imaging of the case together with the review of the literature concerning gliomas.
  • We conclude that each doctor has to be aware of possible neoplasm even in the youngest groups of the patients.
  • [MeSH-major] Glioma / diagnosis. Glioma / surgery. Nose Neoplasms / diagnosis. Nose Neoplasms / surgery
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Male. Nasal Obstruction / etiology. Nasal Obstruction / surgery. Nasal Polyps / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471200.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


95. Molina Saera J, Segura Huerta A, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, Reynés Muntaner G: [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma]. Clin Transl Oncol; 2005 Apr;7(3):127-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].
  • [Transliterated title] Afectación extracraneal de oligoastrocitoma anaplásico desarrollado sobre un glioma de bajo grado.
  • This type of glioma has a favourable prognosis compared to other brain tumours.
  • We present a patient who had received treatment previously for a lowgrade glioma and who subsequently developed an anaplastic oligoastrocytoma in the same zone together with skull and extra-cranial involvement in the disease progression.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Glioma / surgery. Neoplasms, Second Primary / pathology. Skull Neoplasms / pathology. Temporal Bone. Temporal Lobe

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899221.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


96. Aguirre-Balsalobre FE, Coloma-González IT, Mengual-Verdú EN: [Optic nerve glioma in a case of neurofibromatosis-1 in a child]. Arch Soc Esp Oftalmol; 2006 Jan;81(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic nerve glioma in a case of neurofibromatosis-1 in a child].
  • [Transliterated title] Glioma de nervio óptico en un caso de neurofibromatosis-1 infantil.
  • CLINICAL CASE: The case of a three-year-old patient with neurofibromatosis type I is presented.
  • Ophthalmologic evaluation revealed, by means of magnetic resonance imaging, the presence of a silent glioma in the optic nerve of the left eye.
  • DISCUSSION: Neurofibromatosis-1 can present in multiple ways to the ophthalmologist, with a glioma of the optic nerve being one of the most frequent central nervous system presentations in this illness.
  • Generally the glioma affects the optic chiasm and its course is indolent, with conservative management and close monitoring usually being advised until progression is defined.
  • [MeSH-major] Neurofibromatoses / complications. Optic Nerve Glioma / complications

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450259.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


97. Norden AD, Wen PY: Glioma therapy in adults. Neurologist; 2006 Nov;12(6):279-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma therapy in adults.
  • BACKGROUND: Gliomas are the most common type of primary brain tumor.
  • Nearly two-thirds of gliomas are highly malignant lesions that account for a disproportionate share of brain tumor-related morbidity and mortality.
  • Even among patients with low-grade gliomas that confer a relatively good prognosis, treatment is almost never curative.
  • REVIEW SUMMARY: Surgery and radiation have been the mainstays of therapy for most glioma patients, but temozolomide chemotherapy has recently been proven to prolong overall survival in patients with glioblastoma.
  • Intriguing data suggests that activity of O6-methylguanine-DNA methyltransferase (MGMT), in tumor cells may predict responsiveness to temozolomide and other alkylating agents.
  • Novel treatment approaches, especially targeted molecular therapies against critical components of glioma signaling pathways, appear promising in preliminary studies.
  • Optimal treatment for patients with low-grade gliomas has yet to be determined.
  • Advances in oligodendroglioma biology have identified loss of chromosomes 1p and 19q as powerful indicators of a favorable prognosis.
  • CONCLUSIONS: Though the prognosis for many patients with gliomas is poor, the last decade produced a number of important advances, some of which have translated directly into survival benefits.
  • Rapid progress in the field of glioma molecular biology continues to identify therapeutic targets and provide hope for the future of this challenging disease.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122724.001).
  • [ISSN] 1074-7931
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 139
  •  go-up   go-down


98. Quant EC, Drappatz J, Wen PY, Norden AD: Recurrent high-grade glioma. Curr Treat Options Neurol; 2010 Jul;12(4):321-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent high-grade glioma.
  • OPINION STATEMENT: Opinions vary on the best treatment options for recurrent high-grade glioma.
  • Age, performance status, histology, tumor size and location, O6-methylguanine-DNA methyltransferase (MGMT) methylation status for glioblastoma, 1p/19q status for oligodendroglial tumors, and the number and types of prior therapies are important considerations.
  • In addition, recurrent disease must be distinguished from "pseudoprogression" due to treatment effects.
  • Enrollment in a clinical trial is the optimal choice for most patients with recurrent high-grade glioma after failure of radiation therapy and temozolomide.
  • Involved-field external beam radiation should be considered for patients with anaplastic gliomas who have not received radiation.
  • Oligodendroglial tumors with 1p/19q deletions are more likely to respond to treatment.
  • In the past, carmustine was commonly used to treat recurrent high-grade glioma, but the utility of carmustine in the modern era is unknown because most studies were performed prior to the widespread use of temozolomide.
  • High-precision re-irradiation such as stereotactic radiosurgery is another option in high-grade glioma, especially for patients with poor bone marrow reserve or inability to tolerate chemotherapy, but there is a paucity of studies with adequate controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842591.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Genol I, Troyano J, Ariño M, Iglesias I, Arriola P, García-Sánchez J: [Meningocele, glioma and optic nerve meningioma: differential diagnosis and treatment]. Arch Soc Esp Oftalmol; 2009 Nov;84(11):563-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningocele, glioma and optic nerve meningioma: differential diagnosis and treatment].
  • [Transliterated title] Meningocele, glioma y meningioma del nervio óptico: diagnóstico diferencial y tratamiento.
  • PURPOSE: After studying 3 clinical cases, we have reviewed the clinical and radiological characteristics of meningocele, meningioma and optic nerve glioma.
  • The differential diagnosis and therapeutic management are also discussed.
  • METHODS: Review of three clinical reports of three patients seen in our unit and a bibliographic search concerning the diagnosis and therapeutic management of these three entities at the present time.
  • RESULTS: Differential diagnosis has to be based on a wide range of parameters: epidemiologic (age, race, sex, prevalence of the tumors), clinical (visual acuity, perimetry, Hertel exophthalmometry and funduscopy) and radiologic (computed tomography and magnetic resonance).
  • CONCLUSION: A correct differential diagnosis is mandatory to be able to individualize the treatment for each entity (Arch Soc Esp Oftalmol 2009; 84: 563-568).
  • [MeSH-major] Meningioma / diagnosis. Meningioma / therapy. Meningocele / diagnosis. Meningocele / therapy. Optic Nerve Neoplasms / diagnosis. Optic Nerve Neoplasms / therapy
  • [MeSH-minor] Adult. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / therapy

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningocele.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967609.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


100. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR: Glioma pathophysiology: insights emerging from proteomics. Brain Pathol; 2010 Jul;20(4):691-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma pathophysiology: insights emerging from proteomics.
  • Proteomics is increasingly employed in both neurological and oncological research to provide insight into the molecular basis of disease but rarely has a coherent, novel pathophysiological insight emerged.
  • Gliomas account for >50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common.
  • In glioma, the application of proteomic technology has identified altered protein expression but without consistency of these alterations or their biological significance being established.
  • A systematic review of multiple independent proteomic analyses of glioma has demonstrated alterations of 99 different proteins.
  • Importantly 10 of the 99 proteins found differentially expressed in glioma [PHB, Hsp20, serum albumin, epidermal growth factor receptor (EGFR), EA-15, RhoGDI, APOA1, GFAP, HSP70, PDIA3] were identified in multiple publications.
  • The protein network discovered (containing TP53 and RB1 at its core) compliments recent findings in genomic studies of malignant glioma.
  • The novel perspective provided by network analysis indicates that the potential of this technology to explore crucial aspects of glioma pathophysiology can now be realized but only if the conceptual and technical limitations highlighted in this review are addressed.






Advertisement